149 related articles for article (PubMed ID: 28423208)
1. Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
Niessner H; Kosnopfel C; Sinnberg T; Beck D; Krieg K; Wanke I; Lasithiotakis K; Bonin M; Garbe C; Meier F
Exp Dermatol; 2017 Jul; 26(7):598-606. PubMed ID: 28423208
[TBL] [Abstract][Full Text] [Related]
2. Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.
Etnyre D; Stone AL; Fong JT; Jacobs RJ; Uppada SB; Botting GM; Rajanna S; Moravec DN; Shambannagari MR; Crees Z; Girard J; Bertram C; Puri N
Cancer Biol Ther; 2014 Sep; 15(9):1129-41. PubMed ID: 24914950
[TBL] [Abstract][Full Text] [Related]
3. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
4. In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
Daphu I; Horn S; Stieber D; Varughese JK; Spriet E; Dale HA; Skaftnesmo KO; Bjerkvig R; Thorsen F
Int J Mol Sci; 2014 May; 15(5):8773-94. PubMed ID: 24840574
[TBL] [Abstract][Full Text] [Related]
5. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.
Sinnberg T; Lasithiotakis K; Niessner H; Schittek B; Flaherty KT; Kulms D; Maczey E; Campos M; Gogel J; Garbe C; Meier F
J Invest Dermatol; 2009 Jun; 129(6):1500-15. PubMed ID: 19078992
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.
Dronca RS; Allred JB; Perez DG; Nevala WK; Lieser EA; Thompson M; Maples WJ; Creagan ET; Pockaj BA; Kaur JS; Moore TD; Marchello BT; Markovic SN
Am J Clin Oncol; 2014 Aug; 37(4):369-76. PubMed ID: 23357973
[TBL] [Abstract][Full Text] [Related]
9. B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Roos WP; Quiros S; Krumm A; Merz S; Switzeny OJ; Christmann M; Loquai C; Kaina B
Oncotarget; 2014 Dec; 5(24):12607-20. PubMed ID: 25557167
[TBL] [Abstract][Full Text] [Related]
10. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
11. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
12. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
Calero R; Morchon E; Martinez-Argudo I; Serrano R
Cancer Lett; 2017 Oct; 406():1-11. PubMed ID: 28774796
[TBL] [Abstract][Full Text] [Related]
14. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
15. Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas.
Ingels A; Dinhof C; Garg AD; Maddau L; Masi M; Evidente A; Berger W; Dejaegher B; Mathieu V
Cancer Chemother Pharmacol; 2017 May; 79(5):971-983. PubMed ID: 28389780
[TBL] [Abstract][Full Text] [Related]
16. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Ueno T; Ko SH; Grubbs E; Yoshimoto Y; Augustine C; Abdel-Wahab Z; Cheng TY; Abdel-Wahab OI; Pruitt SK; Friedman HS; Tyler DS
Mol Cancer Ther; 2006 Mar; 5(3):732-8. PubMed ID: 16546988
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
[TBL] [Abstract][Full Text] [Related]
18. Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma.
Kang HG; Wang BZ; Zhang J; Liu MR; Li YX
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):197-203. PubMed ID: 27863926
[TBL] [Abstract][Full Text] [Related]
19. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Atif F; Patel NR; Yousuf S; Stein DG
PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
[TBL] [Abstract][Full Text] [Related]
20. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.
Meier F; Guenova E; Clasen S; Eigentler T; Forschner A; Leiter U; Zielinski C; Knaudt B; Garbe C; Berneburg M
J Am Acad Dermatol; 2009 May; 60(5):863-8. PubMed ID: 19389529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
